A5075911054- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Renal cell carcinoma treatment
- Breast Lesions and Carcinomas
- Bone health and treatments
- Radiopharmaceutical Chemistry and Applications
- Ovarian cancer diagnosis and treatment
- Prostate Cancer Treatment and Research
- Peptidase Inhibition and Analysis
- Renal Transplantation Outcomes and Treatments
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Testicular diseases and treatments
- Reproductive Biology and Fertility
- Neuroblastoma Research and Treatments
- Global Cancer Incidence and Screening
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
Ospedale Misericordia - Grosseto
2014-2024
Azienda Ospedaliera Universitaria Pisana
2014-2024
University of Modena and Reggio Emilia
2005-2012
München Klinik
2007
Nuremberg Hospital
2007
Helios Dr. Horst Schmidt Kliniken Wiesbaden
2007
Ospedale Santa Chiara
1999-2006
Fondazione IRCCS Istituto Nazionale dei Tumori
1990
The therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors (AIs), selective modulators (SERMs), and degraders (SERDs). Fulvestrant is the first approved SERD proven efficacy good tolerability in clinical practice. However, secondary drug resistance, low affinity, parental administration stimulated search for new oral SERDs opening a era ER + cancer. Elacestrant an orally bioavailable that has been recently by FDA...
In spite of the effectiveness endocrine therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitors as first-line treatment for estrogen receptor (ER)-positive, erb-b2 tyrosine 2 (ERBB2 [formerly HER2/neu])-negative (ER+/ERBB2-) metastatic breast cancer (MBC), patients eventually develop resistance, and most will receive chemotherapy. The METEORA-II trial compared a metronomic all-oral with intravenous (IV)
Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy uncommon. A randomized trial comparing high-dose sequential with peripheral blood stem cell (PBSC) support platinum-based combination was conducted to investigate whether dose-intensification improves outcome.One hundred forty-nine patients untreated were randomly assigned debulking receive standard or (HD) treatment two cycles cyclophosphamide paclitaxel followed by...
HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MBC) patients treated with high-dose chemotherapy (HDC). status also predictive factor when trastuzumab administered combination or sequentially chemotherapy, significant disease-free and/or overall survival improvement has been observed HER-2+ early MBC. Unfortunately, both settings, an increased risk of cardiac dysfunction (CD). We have reviewed the clinical charts HER-2-overexpressing MBC...
<h3>Importance</h3> Bone resorption inhibitors (BRIs) are recommended by international guidelines to prevent skeletal-related events (SREs) among patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. Abiraterone acetate prednisone is currently the most common first-line therapy for treatment of mCRPC; however, clinical impact addition BRIs abiraterone in this disease setting unknown. <h3>Objective</h3> To evaluate association use concomitant overall...
Highlights•Maintenance everolimus plus AIs did not show significant PFS prolongation over AIs.•A higher number of disease progression as best response was observed in the AI arm.•Taking into account tolerability, maintenance endocrine therapy remains standard.AbstractBackgroundDespite being mainstay treatment for hormone receptor positive (HR+)/HER2− metastatic breast cancer, patients at risk visceral crisis or doubt sensitivity are still offered first-line chemotherapy. Maintenance hormonal...
Abstract Background Although the efficacy of molecularly target agents in vitro, their use routine setting is limited mainly to anti‐HER2 and antiEGFR vivo. Moreover, core biopsy a single cancer site may not be representative whole expanding clones molecular profile at relapse differ with respect primary tumor. Methods We assessed status large panel driver genes by cell‐free DNA (cfDNA) analysis cohort 68 patients 13 different solid tumors disease progression. Whenever possible, second cfDNA...
The efficacy of high-dose chemotherapy (HDC) and autologous hemopoietic progenitor cell transplantation (AHPCT) for breast cancer (BC) patients has been an area intense controversy among the medical oncology community. aim this study was to assess toxicity procedure in a large cohort high-risk primary BC who underwent AHPCT Italy. A total 1183 receiving HDC (HRBC) (>3 positive nodes) were identified Italian registry. median age 46 years, 62% premenopausal at treatment, 60.1% had...
Objectives: Never-smokers may be a distinct subgroup among patients with advanced non-small cell lung cancer, appearing to benefit less from immunotherapy than smokers. We report results never-smokers enrolled in the Italian cohort of nivolumab expanded access program pre-treated squamous cancer. Materials and methods: Nivolumab (3 mg/kg every 2 weeks for ≤24 months) was available on physician request. Efficacy data included objective tumor response, date progression, survival information....
TPS4602 Background: Despite recent advances in drug therapy, pts with mRCC have about a 10% 5-year survival rate. Several preclinical studies documented an increase peripheral antitumour immunity following radiation, phenomenon known as the abscopal effect. NIVO is anti-programmed cell death-1 (PD-1) monoclonal antibody that blocks tumour growth different ways by targeting certain cells. It might work even better when combined SBRT. The irradiated death can enhance antitumor inducing antigen...
<h3>Introduction/Background</h3> Recurrent gynecological tumors (eg, endometrial and ovarian cancers) are incurable diseases; therefore, new treatment options urgently needed. The PTEN-AKT-PI3K pathway is frequently altered in these tumors, representing a potential target. Alpelisib an α-specific PI3K inhibitor approved PIK3CA-mutated advanced breast cancer. We report outcomes from large series of patients with cancers prospectively treated alpelisib within controlled program....
Background Liquid biopsy is mainly used to identify tumor cells in pulmonary neoplasms. It more often research than clinical practice. The BL-MOL-AR study aims investigate the efficacy of next-generation sequencing (NGS) and interpretation circulating free DNA (cfDNA) levels. This reports preliminary results from first samples analyzed patients affected by various neoplasms: lung, intestinal, mammary, gastric, biliary, cutaneous. Methods Biopsia Liquida-Molecolare-Arezzo enroll cancer...
The aim of the study is to evaluate predictive factors response induction chemotherapy in patients with resectable NSCLC, treated at unit Thoracic Surgery Siena University Hospital radical surgery. From January 1, 2013 December 31, 2020, 78 were recruited. We analyzed outcomes terms 5-years OS based on Estimated Regression Rate, N2 downstaging and age; two patients’ subgroups created by age (Group A: &amp;lt;66 years-old; Group B: &amp;gt;66 years-old). No 5-year difference was...